XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia

The main objective of this study is to observe and evaluate the safety and tolerability of the XP-005 personalized tumor mRNA vaccine, either alone or in combination with toripalimab, for the treatment of acute myeloid leukemia patients who are in remission with minimal residual disease (MRD) positive but cannot undergo allogeneic hematopoietic stem cell transplantation.

Trial Details

NCT ID
NCT06980155
Phase
EARLY_PHASE1
Sponsor
Shanghai Jiao Tong University School of Medicine
Status
RECRUITING
Cancer Type
Acute Myeloid (AML) Leukemia
Interventions
  • Personalized neoantigen tumor vaccine
  • PD-1 inhibitor
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Subject voluntarily signs the written informed consent form and is able to comply with the scheduled visits and related procedures specified in the…
  • Subject must be ≥ 18 years old, with no gender restrictions
  • The expected survival period is ≥3 months
  • Conforming to the World Health Organization (WHO) 2022 classification criteria for Acute Myeloid Leukemia (AML).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Myeloid (AML) Leukemia Trials on Trialify →